首页> 外文期刊>Indian journal of Anaesthesia >Are All Colloids Same? How to Select the Right Colloid?
【24h】

Are All Colloids Same? How to Select the Right Colloid?

机译:所有胶体都一样吗?如何选择正确的胶体?

获取原文
       

摘要

SummaryThe administration of intravenous fluids is one of the most common and universal interventions in medicine. Colloids are an alternative to the frequently used crystalloids, with highly variable use depending on a myriad of clinical variables. A colloid is defined as a high molecular weight (MW) substance that largely remains in the intravascular compartment, thereby generating an oncotic pressure. Colloids are considered to have a greater intravascular persistence when compared to crystalloids. All colloids, however, are clearly not the same. Differences in the physicochemical properties, pharmacokinetics and safety profile exist amongst various colloids. This review explores the different types of colloids, with their properties and usefulness as well as adverse effects. While all the available colloids are reviewed briefly (e.g., albumin, gelatin, dextran) with respect to their pharmacology, indications, advantages and disadvantages, particular emphasis is laid on the hydroxyethyl starches (HES) because of their rising prominence. It is shown that HES differ widely in their physicochemical and pharmacokinetic properties, composition, usefulness, and especially in their adverse effect profiles. The third generation HES (tetrastarches), in particular, seem to offer a unique combination of safety and efficacy. Several issues related to this are discussed in detail. This review of the available clinical data demonstrates that HES should not be regarded as one homogenous group, and data for one product should not be automatically extrapolated to another. Thus, among the synthetic colloids, the tetrastarches appear to offer the best currently available compromise between efficacy, safety profile, and cost. They also appear to be the best suited for use in the intensive care setting. Finally, balanced (rather than saline-based) HES solutions appear promising as a plasma-adapted volume replacement strategy and may further refine the ongoing quest of finding the ideal fluid therapy.
机译:总结静脉输液的管理是医学界最普遍的干预措施之一。胶体是经常使用的晶体的替代品,其用途取决于多种临床变量。胶体被定义为高分子量(MW)物质,该物质大部分保留在血管内腔室中,从而产生溶细胞压。与晶体相比,胶体被认为具有更大的血管内持久性。但是,所有胶体显然都不相同。各种胶体之间在理化特性,药代动力学和安全性方面存在差异。这篇综述探讨了不同类型的胶体,以及它们的性质,有用性和不利影响。尽管简要概述了所有可用的胶体(例如白蛋白,明胶,右旋糖酐)的药理学,适应症,优缺点,但由于羟乙基淀粉(HES)的突出性,因此特别强调了羟乙基淀粉(HES)。结果表明,HES的理化和药代动力学特性,组成,有用性,尤其是其不良反应特征差异很大。特别是第三代HES(四淀粉)似乎提供了安全性和功效的独特组合。详细讨论了与此有关的几个问题。对现有临床数据的审查表明,不应将HES视为一个同类组,并且不应将一种产品的数据自动推断到另一种产品。因此,在合成胶体中,四淀粉似乎在功效,安全性和成本之间提供了目前最好的折衷方案。它们似乎也最适合用于重症监护环境。最后,平衡的(而不是基于盐水的)HES解决方案有望作为血浆适应的容积替代策略,并且可能会进一步完善寻找理想流体疗法的过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号